EGFR and lung cancer: Such mechanisms include; the Thr790Met mutation in the epidermal growth factor receptor (EGFR) which induces resistance to tyrosine kinase inhibitors (TKIs) (215), and tumor-reprogramming of the lung microenvironment which induces resistance to angiogenesis and immune checkpoint molecular target therapies in lung cancer (216).